Listen to part II of our #ACR20 Day 3 recap. Follow the link below or find us on Apple podcasts. https://t.co/1TcXfU5TMg https://t.co/evGkn9UARB

• https://bit.ly/2U7iReS

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit @RheumNow #ACR20 https://t.co/DHfHYJCkod

Patient-physician discordance seen in ~30% #rheumatoidarthritis patients starting #DMARDs - ↑Patient-reported pain & functional impairment assoc. w/ discordance - Patient-centric treatment discussions needed to reduce discordance Abs#1978 #ACR20 @RheumNow https://t.co/CdlHrBOdy0

• Prevalence and Factors Associated with Patient-Physician Discordance Among RA P…

The avacopan story, stronger again: (recall: avacopan targets C5aR) endogenous anti-C5aR1 in GPA inversely correlates with dx activity, relapse questions, via chair @philseo: What happens to anti-C5aR1 with Rx? Does this influence therapeutic strategy? #ACR20 ABST2050 @RheumNow https://t.co/g4JfjQal8R

Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow

Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @rheumnow @DrPujaMehta1 #ACR20 Abstr#L06 #ACRbest https://t.co/MTuH0sAuWt

You have a patient with RA on 25 mg MTX SQ, tolerating well without side effects. They have moderate disease activity. Your next step: @Rheumnow. #ACR20

New #ACR RA guidelines is cost conscious: 1. DMARD naive: Preferred MTX over LEF>HCQ/SSZ and preferred MTX over biologic/tsDMARD 2. DMARD naive low DAS: HCQ or SSZ preferred >MTX>LEF 3. T2T goal LDA/remission @rheumnow (thread)

Hepatitis B infexn in RA? Below is the ACR 2020 draft treatment guidelines in this patient population: @RheumNow #ACR20 https://t.co/C3zw4TWOpg

Here is rationale for this recommendation away from triple therapy even though it has not shown to be inferior treatment, but works better/better adherence #ACR20 @Rheumnow. https://t.co/fQPOjLEjoA https://t.co/XrimgQW7oH

• https://twitter.com/ejdein1/status/1325834736569356290

Switching or adding a DMARD in pts w/ moderate-high dz RA activity & hx of previous serious infection w/in the past 12 mos as opposed to starting/increasing GCs is conditionally recommended per draft recs of new ACR RA treatment guidelines. #ACR20 @rheumnow @CCalabreseDO

Draft #ACR20 Rx Recs for RA: MTX is conditionally recommended with NORMAL LFTs and no advanced fibrosis. Role of HCQ for NALFD has been suggested at ACR, but not enough for mod-high disease activity @RheumNow. https://t.co/QFF3BK1NF0

New #ACR20 draft guidelines for RA treatment @RheumNow https://t.co/j8jUdgM4dD

• https://twitter.com/EBRheum/status/1325835188820176897